Atlas Trials

Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial

Clinical trial NCT05804656 · COMPLETED

Trial details

NCT number
NCT05804656
Sponsor
CKD Bio Corporation
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Glabellar Lines
Start date
2023-04-13
Primary completion
2023-08-29
Enrollment
300

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.